168 related articles for article (PubMed ID: 2590999)
1. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
2. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
3. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
4. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
5. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
8. Development of alkylating agent-resistant human tumor cell lines.
Teicher BA; Frei E
Cancer Chemother Pharmacol; 1988; 21(4):292-8. PubMed ID: 3370736
[TBL] [Abstract][Full Text] [Related]
9. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
11. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
12. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
13. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
Villa R; Zaffaroni N; Orlandi L; Bearzatto A; Costa A; Silvestrini R
Eur J Cancer; 1994; 30A(10):1534-40. PubMed ID: 7833114
[TBL] [Abstract][Full Text] [Related]
15. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
17. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
Raaphorst GP; Ko D; Feeley MM; Danjoux CE; Maroun J; Evans WK
Anticancer Res; 1991; 11(1):41-7. PubMed ID: 2018379
[TBL] [Abstract][Full Text] [Related]
18. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher BA; Bernal SD; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
[TBL] [Abstract][Full Text] [Related]
20. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
Savini S; Zoli W; Nanni O; Volpi A; Frassineti GL; Magni E; Flamigni A; Amadori A; Amadori D
Breast Cancer Res Treat; 1992; 24(1):27-34. PubMed ID: 1463869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
